Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country
The goal of this study was to assess the 6-month effectiveness of hybrid closed loop on glycemic control in type 1 diabetes (T1D) patients in Latin America. An exploratory analysis of data prospectively collected from non-selected consecutive patients with T1D who initiated treatment with the MiniMe...
Gespeichert in:
| Veröffentlicht in: | Diabetes technology & therapeutics 2022-03, Vol.24 (3), p.220-226 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 226 |
|---|---|
| container_issue | 3 |
| container_start_page | 220 |
| container_title | Diabetes technology & therapeutics |
| container_volume | 24 |
| creator | Proietti, Adrian Raggio, Marcela Paz, María Rubin, Graciela Kabakian, María Saleme, Antonio Grosembacher, Luis |
| description | The goal of this study was to assess the 6-month effectiveness of hybrid closed loop on glycemic control in type 1 diabetes (T1D) patients in Latin America. An exploratory analysis of data prospectively collected from non-selected consecutive patients with T1D who initiated treatment with the MiniMed™ 670G system in Argentina was conducted. Baseline and follow-up visits at days 7, 28, 90, and 180 were carried out and data were downloaded at each visit. A total of 30 patients (age range 9-57 years, female 63.3%), 73.3% (
= 22) of whom previously used sensor augmented pump-predictive low glucose management (SAP-PLGM), with baseline glycated hemoglobin 7.4% ± 1% were included. Time in range between 70 and 180 mg/dL significantly increased from 65.1% at baseline to 77.3%, 76.2%, 75.7%, and 75.2% at days 7, 28, 90 and 180, respectively. Time above range (>180 mg/dL) significantly decreased from 33% to 22.5% (
|
| doi_str_mv | 10.1089/dia.2021.0248 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2584016881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584016881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c321t-b90e669622f3812d94b71ffc0ce777ea1f7d8f6ef045364f2fd7cbe3dc7a31063</originalsourceid><addsrcrecordid>eNpdkUtr3DAUhUVpaCbTLrstgm6y8UQPW5KXw7R5wIQEkq6FLF9RBduaSjaJ_31kJukiq_v6OBzuQeg7JRtKVH3RerNhhNENYaX6hFa0qmShqpp_XnpGippW4hSdpfRECJGc0S_olJdCKKnYCqUH_1LchmH8i6-62ULvLd7lMYYOP_u8Nfh6bqJv8a4LCdpiH8IBP8xphB77AT_OB8AU__KmgRESvjejh2FMy83gfZ4GvO0hemuGLDxl5fkrOnGmS_Dtra7Rn8vfj7vrYn93dbPb7gubXY5FUxMQohaMOa4oa-uykdQ5SyxIKcFQJ1vlBDhSVlyUjrlW2gZ4a6XhlAi-RudH3UMM_yZIo-59stB1ZoAwJc0qVRIqlKIZ_fkBfQpTHLI7zQTPr-JUskwVR8rGkFIEpw_R9ybOmhK9pKFzGnpJQy9pZP7Hm-rU9ND-p9_fz18BgjCEiw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638783172</pqid></control><display><type>article</type><title>Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Proietti, Adrian ; Raggio, Marcela ; Paz, María ; Rubin, Graciela ; Kabakian, María ; Saleme, Antonio ; Grosembacher, Luis</creator><creatorcontrib>Proietti, Adrian ; Raggio, Marcela ; Paz, María ; Rubin, Graciela ; Kabakian, María ; Saleme, Antonio ; Grosembacher, Luis</creatorcontrib><description>The goal of this study was to assess the 6-month effectiveness of hybrid closed loop on glycemic control in type 1 diabetes (T1D) patients in Latin America. An exploratory analysis of data prospectively collected from non-selected consecutive patients with T1D who initiated treatment with the MiniMed™ 670G system in Argentina was conducted. Baseline and follow-up visits at days 7, 28, 90, and 180 were carried out and data were downloaded at each visit. A total of 30 patients (age range 9-57 years, female 63.3%), 73.3% (
= 22) of whom previously used sensor augmented pump-predictive low glucose management (SAP-PLGM), with baseline glycated hemoglobin 7.4% ± 1% were included. Time in range between 70 and 180 mg/dL significantly increased from 65.1% at baseline to 77.3%, 76.2%, 75.7%, and 75.2% at days 7, 28, 90 and 180, respectively. Time above range (>180 mg/dL) significantly decreased from 33% to 22.5% (
< 0.001), while time below range (<70 mg/dL) did not change. Mean glucose levels were reduced from 163.5 mg/dL at baseline to 150.9 mg/dL (
= 0.001) at last visit. The Auto Mode feature was used > 90% of the time. Virtual training was successfully completed with a Net Promoter Score
(NPS
) of 87%. This analysis confirms that MiniMed 670G system use allowed successful achievement of glycemic control within recommended targets in a non-selected Latin American patient population who underwent virtual system training.</description><identifier>ISSN: 1520-9156</identifier><identifier>EISSN: 1557-8593</identifier><identifier>DOI: 10.1089/dia.2021.0248</identifier><identifier>PMID: 34668782</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adolescent ; Adult ; Blood Glucose - analysis ; Blood Glucose Self-Monitoring ; Child ; Closed loop systems ; Diabetes ; Diabetes Mellitus, Type 1 - drug therapy ; Disease management ; Female ; Glucose monitoring ; Glycemic Control ; Humans ; Hyperglycemia ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Insulin Infusion Systems ; Latin America ; Medical technology ; Middle Aged ; Sensors ; Young Adult</subject><ispartof>Diabetes technology & therapeutics, 2022-03, Vol.24 (3), p.220-226</ispartof><rights>Copyright Mary Ann Liebert, Inc. Mar 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c321t-b90e669622f3812d94b71ffc0ce777ea1f7d8f6ef045364f2fd7cbe3dc7a31063</citedby><cites>FETCH-LOGICAL-c321t-b90e669622f3812d94b71ffc0ce777ea1f7d8f6ef045364f2fd7cbe3dc7a31063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34668782$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Proietti, Adrian</creatorcontrib><creatorcontrib>Raggio, Marcela</creatorcontrib><creatorcontrib>Paz, María</creatorcontrib><creatorcontrib>Rubin, Graciela</creatorcontrib><creatorcontrib>Kabakian, María</creatorcontrib><creatorcontrib>Saleme, Antonio</creatorcontrib><creatorcontrib>Grosembacher, Luis</creatorcontrib><title>Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country</title><title>Diabetes technology & therapeutics</title><addtitle>Diabetes Technol Ther</addtitle><description>The goal of this study was to assess the 6-month effectiveness of hybrid closed loop on glycemic control in type 1 diabetes (T1D) patients in Latin America. An exploratory analysis of data prospectively collected from non-selected consecutive patients with T1D who initiated treatment with the MiniMed™ 670G system in Argentina was conducted. Baseline and follow-up visits at days 7, 28, 90, and 180 were carried out and data were downloaded at each visit. A total of 30 patients (age range 9-57 years, female 63.3%), 73.3% (
= 22) of whom previously used sensor augmented pump-predictive low glucose management (SAP-PLGM), with baseline glycated hemoglobin 7.4% ± 1% were included. Time in range between 70 and 180 mg/dL significantly increased from 65.1% at baseline to 77.3%, 76.2%, 75.7%, and 75.2% at days 7, 28, 90 and 180, respectively. Time above range (>180 mg/dL) significantly decreased from 33% to 22.5% (
< 0.001), while time below range (<70 mg/dL) did not change. Mean glucose levels were reduced from 163.5 mg/dL at baseline to 150.9 mg/dL (
= 0.001) at last visit. The Auto Mode feature was used > 90% of the time. Virtual training was successfully completed with a Net Promoter Score
(NPS
) of 87%. This analysis confirms that MiniMed 670G system use allowed successful achievement of glycemic control within recommended targets in a non-selected Latin American patient population who underwent virtual system training.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Blood Glucose - analysis</subject><subject>Blood Glucose Self-Monitoring</subject><subject>Child</subject><subject>Closed loop systems</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Disease management</subject><subject>Female</subject><subject>Glucose monitoring</subject><subject>Glycemic Control</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Infusion Systems</subject><subject>Latin America</subject><subject>Medical technology</subject><subject>Middle Aged</subject><subject>Sensors</subject><subject>Young Adult</subject><issn>1520-9156</issn><issn>1557-8593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtr3DAUhUVpaCbTLrstgm6y8UQPW5KXw7R5wIQEkq6FLF9RBduaSjaJ_31kJukiq_v6OBzuQeg7JRtKVH3RerNhhNENYaX6hFa0qmShqpp_XnpGippW4hSdpfRECJGc0S_olJdCKKnYCqUH_1LchmH8i6-62ULvLd7lMYYOP_u8Nfh6bqJv8a4LCdpiH8IBP8xphB77AT_OB8AU__KmgRESvjejh2FMy83gfZ4GvO0hemuGLDxl5fkrOnGmS_Dtra7Rn8vfj7vrYn93dbPb7gubXY5FUxMQohaMOa4oa-uykdQ5SyxIKcFQJ1vlBDhSVlyUjrlW2gZ4a6XhlAi-RudH3UMM_yZIo-59stB1ZoAwJc0qVRIqlKIZ_fkBfQpTHLI7zQTPr-JUskwVR8rGkFIEpw_R9ybOmhK9pKFzGnpJQy9pZP7Hm-rU9ND-p9_fz18BgjCEiw</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Proietti, Adrian</creator><creator>Raggio, Marcela</creator><creator>Paz, María</creator><creator>Rubin, Graciela</creator><creator>Kabakian, María</creator><creator>Saleme, Antonio</creator><creator>Grosembacher, Luis</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202203</creationdate><title>Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country</title><author>Proietti, Adrian ; Raggio, Marcela ; Paz, María ; Rubin, Graciela ; Kabakian, María ; Saleme, Antonio ; Grosembacher, Luis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c321t-b90e669622f3812d94b71ffc0ce777ea1f7d8f6ef045364f2fd7cbe3dc7a31063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Blood Glucose - analysis</topic><topic>Blood Glucose Self-Monitoring</topic><topic>Child</topic><topic>Closed loop systems</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Disease management</topic><topic>Female</topic><topic>Glucose monitoring</topic><topic>Glycemic Control</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Infusion Systems</topic><topic>Latin America</topic><topic>Medical technology</topic><topic>Middle Aged</topic><topic>Sensors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Proietti, Adrian</creatorcontrib><creatorcontrib>Raggio, Marcela</creatorcontrib><creatorcontrib>Paz, María</creatorcontrib><creatorcontrib>Rubin, Graciela</creatorcontrib><creatorcontrib>Kabakian, María</creatorcontrib><creatorcontrib>Saleme, Antonio</creatorcontrib><creatorcontrib>Grosembacher, Luis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes technology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Proietti, Adrian</au><au>Raggio, Marcela</au><au>Paz, María</au><au>Rubin, Graciela</au><au>Kabakian, María</au><au>Saleme, Antonio</au><au>Grosembacher, Luis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country</atitle><jtitle>Diabetes technology & therapeutics</jtitle><addtitle>Diabetes Technol Ther</addtitle><date>2022-03</date><risdate>2022</risdate><volume>24</volume><issue>3</issue><spage>220</spage><epage>226</epage><pages>220-226</pages><issn>1520-9156</issn><eissn>1557-8593</eissn><abstract>The goal of this study was to assess the 6-month effectiveness of hybrid closed loop on glycemic control in type 1 diabetes (T1D) patients in Latin America. An exploratory analysis of data prospectively collected from non-selected consecutive patients with T1D who initiated treatment with the MiniMed™ 670G system in Argentina was conducted. Baseline and follow-up visits at days 7, 28, 90, and 180 were carried out and data were downloaded at each visit. A total of 30 patients (age range 9-57 years, female 63.3%), 73.3% (
= 22) of whom previously used sensor augmented pump-predictive low glucose management (SAP-PLGM), with baseline glycated hemoglobin 7.4% ± 1% were included. Time in range between 70 and 180 mg/dL significantly increased from 65.1% at baseline to 77.3%, 76.2%, 75.7%, and 75.2% at days 7, 28, 90 and 180, respectively. Time above range (>180 mg/dL) significantly decreased from 33% to 22.5% (
< 0.001), while time below range (<70 mg/dL) did not change. Mean glucose levels were reduced from 163.5 mg/dL at baseline to 150.9 mg/dL (
= 0.001) at last visit. The Auto Mode feature was used > 90% of the time. Virtual training was successfully completed with a Net Promoter Score
(NPS
) of 87%. This analysis confirms that MiniMed 670G system use allowed successful achievement of glycemic control within recommended targets in a non-selected Latin American patient population who underwent virtual system training.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>34668782</pmid><doi>10.1089/dia.2021.0248</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-9156 |
| ispartof | Diabetes technology & therapeutics, 2022-03, Vol.24 (3), p.220-226 |
| issn | 1520-9156 1557-8593 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2584016881 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Blood Glucose - analysis Blood Glucose Self-Monitoring Child Closed loop systems Diabetes Diabetes Mellitus, Type 1 - drug therapy Disease management Female Glucose monitoring Glycemic Control Humans Hyperglycemia Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Infusion Systems Latin America Medical technology Middle Aged Sensors Young Adult |
| title | Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T14%3A46%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Six-Month%20Glycemic%20Control%20with%20a%20Hybrid%20Closed-Loop%20System%20in%20Type%201%20Diabetes%20Patients%20in%20a%20Latin%20American%20Country&rft.jtitle=Diabetes%20technology%20&%20therapeutics&rft.au=Proietti,%20Adrian&rft.date=2022-03&rft.volume=24&rft.issue=3&rft.spage=220&rft.epage=226&rft.pages=220-226&rft.issn=1520-9156&rft.eissn=1557-8593&rft_id=info:doi/10.1089/dia.2021.0248&rft_dat=%3Cproquest_cross%3E2584016881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638783172&rft_id=info:pmid/34668782&rfr_iscdi=true |